Company news

Arovella Therapeutics Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Investor Presentation March 2021

March 29, 2021

Anagrelide Project Update

February 25, 2021

Appendix 4D & Interim Financial Half Year Report FY2021

February 25, 2021

Zelira Therapeutics Feasibility Study Update

February 15, 2021

Company Update - Letter to Shareholders

December 21, 2020

Prospectus - Placement

December 15, 2020

Ordesa Feasibility Study Update

December 15, 2020

Placement Offer to raise $2.76m

December 15, 2020

AGM FY20 Chairmans address and virtual meeting guide

November 25, 2020

AGM FY20 Presentation

November 25, 2020

R & D Tax Incentive refund received

November 23, 2020

Investor Presentation November 2020

November 16, 2020

Anagrelide Cancer Patent For Australia

September 8, 2020

Appendix 4C - quarterly

July 31, 2020

TGA Approval Granted For ZolpiMist

July 28, 2020

Prospectus For Entitlement Offer

July 2, 2020

Entitlement Offer To Raise Approximately $3.56 Million

July 2, 2020

Market Update

June 24, 2020

Suspension from Official Quotation

June 4, 2020

Anagrelide Cancer Patent For Japan

May 20, 2020

SUDA Signs Additional Licence With Mitsubishi Tanabe

March 22, 2020

Half Yearly Report and Accounts

February 26, 2020

SANOFI and SUDA Entered Into A Feasibility Agreement

December 8, 2019

SUDA Signs Co-Development Deal With Ordesa

December 4, 2019

SUDA Appoints Dr Michael Baker CEO

November 26, 2019

Case For Share Consolidation and Appendix 3A.3

November 3, 2019

SUDA Finalises Agreement With Cann Pharmaceutical

October 29, 2019

Response to ASX Query regarding Accounts

October 2, 2019

Manaing Director and CEO Resignation

September 23, 2019

ArTiMist Appeal Lodged With TGA

August 8, 2019

ZolpiMist Clinical Results Published

August 6, 2019

European Anagrelide Cancer Patent

July 21, 2019

Supplementary Prospectus

June 27, 2019

Rights Issue Closes Significantly Oversubscribed

June 25, 2019

SUDA SIgns Binding Term Sheet With Cann Pharmaceutical

June 4, 2019

Prospectus For Renounceable Pro Rata Offer

June 2, 2019

Rights Issue To Raise Up To $3.44 Million

June 2, 2019

Product Development Market Update

May 12, 2019

ArTiMist Regulatory Update

April 18, 2019

Appendix 4C Amended

February 4, 2019

SUDA Signs Agreement With Mitsubishi Tanabe

December 18, 2018

ZLD to Invest in Development of Oral Spray Formulations

December 5, 2018

SUDA Enters Agreement To Develop Cannabinoid Spray

December 5, 2018

SUDA Receives R&D Tax Incentive Refund

November 14, 2018

ZolpiMist Market Update

November 12, 2018

SUDA Signs Agreement For SUD-001H For US Market

November 7, 2018

Appendix 4C, Market Update and Top 20

October 28, 2018

Request for Trading Halt

September 11, 2018

SUDA Achieves TGA GMP Licence

August 20, 2018

Business Development Update

July 15, 2018

← Newer news releases · Older news releases →

Decks

The 5 newest of 45 decks. Every deck is listed under its year.